Avacincaptad pegol,
does it really help with Slowed geographic atrophy lesion enlargement in age-related macular degeneration?
research showsAvacincaptad pegol is rated C because GATHER2 slowed lesion growth by about 14% at 12 months (p=0.0064). At two years, BCVA differed by −0.83 letters (p=0.58), low-luminance BCVA by −1.49 (p=0.38), and persistent loss of at least 15 letters had HR 0.90 (p=0.6424), showing no visual-function benefit. This yields C with 46 points.
ads claimA lesion growing less is not the same as vision being preserved, and no vision benefit was confirmed through two years. Slowing atrophy progression must not be rewritten as preserving vision or preventing blindness.
Useful facts when choosing a product
- Avacincaptad pegol is a complement C5 inhibitor injected intravitreally into the affected eye by a qualified professional.
- United States labeling directs 2 mg approximately every 28 days for up to 12 months.
- Intravitreal injection carries risks of endophthalmitis, retinal detachment, and transient intraocular-pressure elevation.
- In trials, exudative or neovascular AMD occurred more often with monthly treatment, 7% versus 4% with sham.
What the research actually shows
GATHER2 was a 448-patient double-masked phase 3 trial. Its 12-month imaging primary endpoint showed about 14% less lesion growth (p=0.0064), an imaging surrogate. At two years, BCVA differed by −0.83 letters (p=0.58), low-luminance BCVA by −1.49 (p=0.38), and persistent loss of at least 15 letters had HR 0.90 (p=0.6424), showing no visual-function benefit.
Why this is classified as C (46)
Replicated imaging efficacy is accepted, but negative two-year visual-function results and rule ①-ⓐ yield C with 46 points, essentially identical to pegcetacoplan in verdict 1604, which is C with 46 points; both slow lesions without preserving vision.
Counterpoint. It treats the same indication as pegcetacoplan in verdict 1604, which is C with 46 points, but targets a different complement component and lacks head-to-head comparison.
Rejudgment record. Cross-check applied — Accepted replicated imaging lesion-growth reduction but applied rule ①-ⓐ because visual clinical benefit was not demonstrated
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Slowed geographic atrophy lesion enlargement | C | The imaging endpoint was positive in multiple trials but remains a surrogate. |
| Preserved vision | D | At two years, the BCVA difference was −0.83 letters (p=0.58), showing no improvement. |
| Improved low-luminance BCVA and other visual function | D | At two years, the low-luminance BCVA difference was −1.49 letters (p=0.38) and persistent loss of at least 15 letters had HR 0.90 (p=0.6424), showing no benefit. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Khanani AM et al. 2023 GATHER2 | Peer-reviewed original phase 3 double-masked randomized sham-controlled trial | 448 | Iveric Bio | Primary: geographic atrophy lesion growth at 12 months | Primary endpoint met; lesion growth reduced by 14%, p=0.0064. | Pivotal phase 3 imaging-surrogate evidence |
| Jaffe GJ et al. 2021 GATHER1 | Peer-reviewed original phase 2/3 randomized sham-controlled trial | 286 | Iveric Bio | Imaging lesion growth at 12 months | The 2-mg group had 27.4% less lesion growth, p=0.0072. | Replicating imaging evidence |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-24).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] Avacincaptad pegol x slowed geographic atrophy lesion enlargement — Evidence Grade C·46. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/eye/avacincaptad-pegol-geographic-atrophy-lesion-growth/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.